Background Multiple myeloma is a malignant disease of plasma cells with a worldwide
incidence of 6–7 cases per 100 000 persons per year. It is among the 20 most common …

Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …

Abstract The European Myeloma Network provides recommendations for the management
of the most common complications of multiple myeloma. Whole body low-dose computed …

Purpose The aim of the International Myeloma Working Group was to develop practice
recommendations for the management of multiple myeloma (MM)–related bone disease …

Multiple myeloma management has undergone profound changes in the past thanks to
advances in our understanding of the disease biology and improvements in treatment and …

Recent developments have led to remarkable improvements in the assessment and
treatment of patients with multiple myeloma (MM). New technologies have become available …

Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of
monoclonal plasma cells localized within the bone marrow. Bone disease with associated …

Background Zoledronic acid reduces skeletal-related events in patients with breast cancer,
but concerns have been raised about prolonged monthly administration. We assessed the …

Multiple myeloma represents 2% of all new cancer diagnoses in the United Kingdom and
accounts for 2% of all cancer deaths. In the past few decades, there have been huge …